Breaking Finance News

Spectranetics Corp (NASDAQ:SPNC) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Spectranetics Corp (NASDAQ:SPNC) to Sell in a statement released on 1/11/2017.

Having a price of $25.20, Spectranetics Corp (NASDAQ:SPNC) traded -2.58% lower on the day. With the last stock price up 5.84% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.04% over the same period. SPNC has recorded a 50-day average of $23.89 and a two hundred day average of $23.15. Trade Volume was down over the average, with 64,568 shares of SPNC changing hands under the typical 407,197

Recent Performance Chart

Spectranetics Corp (NASDAQ:SPNC)

Spectranetics Corp has with a one year low of $11.09 and a one year high of $25.81 and has a market capitalization of $0.

A total of 11 brokerages have released a report on Spectranetics Corp. Four brokerages rating the company a strong buy, four brokerages rating the company a buy, two brokerages rating the company a hold, one brokerage rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $20.05.

General Company Details For Spectranetics Corp (NASDAQ:SPNC)

The Spectranetics Corporation is a United States-based company, which develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to cross, prepare and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The Company's segments include U.S. Medical and International Medical. The U.S. Medical segment offers medical devices, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment), and the service of the excimer laser system (service). The International Medical segment serves Europe, the Middle East, Asia Pacific, Latin America and Puerto Rico, and provides Stellarex DCB and AngioSculptX products, which are available for sale in Europe. The Company's solutions include Lead Management, Peripheral Intervention and Coronary Intervention.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *